Jeff E. Knight - 16 Mar 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Chief Operating Officer
Issuer ticker: CRNX
Reported as of: 16 Mar 2023
Net transaction value: -$10,049
SEC form: 4
Accepted by SEC: 17 Mar 2023, 17:08:29 UTC
Prior SEC filing: 03 Mar 2023
Next SEC filing: 12 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Marc Wilson, as attorney-in-fact

Key filing fact

Jeff E. Knight filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 17 Mar 2023.

Key facts

This page summarizes Jeff E. Knight's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2023, 17:08.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: -$10,049.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Tax liability

Transaction value: $10,049
Shares: -587
Change %: -1.7%
Price: $17.12
Shares after: 34,400
Date: 16 Mar 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.